CRBN-based GSPT1 molecular glue degrader

intravenous agent in Ph. I for AML + MDS

from phenotypic screen of CRBN mod library

J. Med. Chem., Feb. 16, 2021

Celgene/Bristol Myers Squibb, San Diego, CA

1. The Bristol Myers Squibb (BMS)/Celgene GSPT1 degrader (CC-90009) is a CRBN-based molecular glue (CELMoD). It is a clinical candidate in Ph. I for AML and MDS, and in…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.